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B A C K G R O U N D
Breast cancer is the most common cause of cancer and cancer mortality in women worldwide (Ferlay 2000) . Metastatic breast cancer occurs when the cancer has spread beyond the breast and regional node areas. Breast cancer can progress to metastatic disease despite a range of adjuvant systemic therapies. Once breast cancer is metastatic, it is no longer curable but it is treatable. The aim of any further treatment is to improve the individual's quality and length of life.
Endocrine therapy removes the influence of oestrogen on breast cancer cells, preventing the cancer cells from growing and spreading and has been shown to improve survival in early breast cancer. Early methods of therapy consisted of endocrine organ ablation by surgery (Beatson 1896) but these procedures have largely been superseded by effective hormonal treatments.
Most endocrine therapies either block the binding of oestrogen to its receptor or reduce serum and tumour concentrations of oestrogen. A positive initial response to endocrine treatment is a good indication for use of second and even third-line endocrine therapy until the disease becomes hormone resistant (Roseman 1997).
The most important predictor of response to hormone therapy is the oestrogen receptor (ER) status of the original tumour.
Currently, the most widely-used endocrine therapy for treatment of hormone-sensitive metastatic disease is tamoxifen (Howell 1997) . Tamoxifen is an oral, non-steroidal competitive ER antagonist. Tamoxifen, however, also has an agonist effect and although patients may relapse and develop acquired resistance to tamoxifen, this does not mean that they will not respond to other endocrine therapy.
Other endocrine therapies used in this setting are fulvestrant, megestrol acetate (MA) and medroxyprogesterone acetate (MPA). Fulvestrant is an ER antagonist that downregulates the ER and reduces progesterone receptor content but, unlike tamoxifen, does not have an agonist effect. It is used as a treatment for tamoxifenresistant advanced disease. MPA and MA are oral progestogens which have been shown to have significant antitumour activity after failure of other endocrine therapies in postmenopausal patients.
In postmenopausal women, oestrogen is no longer produced in the ovaries but androgens (mainly from the adrenal glands) are converted into oestrogens in peripheral tissue by the enzyme aromatase (Miller 1996a) . Aromatase inhibitors (AIs) are a class of compounds that act systemically to inhibit oestrogen synthesis in tissues. AIs are of two types, reversible and irreversible; both types of inhibitors compete with normal substrates for binding on the enzyme. The non-competitive inhibitors (which are steroidal) leave the enzyme permanently inactivated (Ibrahim 1995).
AIs are classified as either first, second or third generation. Aminoglutethimide (AG) was the first AI and although effective it was poorly tolerated. This was supplanted by 4-hydroxy androstenedione (formestane) which was better tolerated. Third generation AIs fall into two principal categories (a) non-steroidal, reversible triazole derivatives (anastrozole, fadrozole, letrozole, vorozole ) and (b) steroidal, irreversible inhibitors (exemestane). The most widely used AIs are currently anastrozole, exemestane and letrozole.
AIs have a different toxicity profile to other endocrine therapies, although some that mimic menopausal symptoms due to depletion of oestrogen are the same, such as hot flushes and sweating. Adverse events particular to AIs include stomach upsets (nausea, vomiting, diarrhoea), rash and arthralgia. AG was poorly tolerated and can cause drowsiness, fever and inhibition of cortisol synthesis. Formestane, although generally well-tolerated as a treatment, resulted in local reaction around the injection site. Tamoxifen which was most widely used before AIs, can cause endometrial changes including vaginal bleeding and increased risk of thromboembolic events. Side effects with progestogens are usually mild but may may include hot flushes, night sweats, nausea and indigestion, fluid retention, weight gain and headaches as well as an increased risk of thromboembolism. Fulvestrant can have similar oestrogen deprivation side effects, injection site reactions, vomiting and diarrhoea.
AIs are now being used increasingly in the treatment of early breast cancer which may have an impact on their use in advanced (metastatic) disease.
O B J E C T I V E S
The aim of this systematic review was to compare aromatase inhibitors to other endocrine therapy in the treatment of advanced (metastatic) breast cancer in postmenopausal women.
M E T H O D S Criteria for considering studies for this review

Types of studies
Only randomised controlled studies in the following populations were included:
• trials of patients with advanced (metastatic) breast cancer • trials with results stratified by stage of disease so that it was possible to identify the subgroup of patients with advanced or metastatic breast cancer
Types of participants
Postmenopausal women with advanced or metastatic breast cancer either at diagnosis or upon relapse
• excluding those with local recurrence only;
• oestrogen receptor (ER) positive or status unknown;
• with no restrictions on metastatic site or age of the women;
• inclusion not limited to use of an AI as first-line therapy.
Types of interventions
• Aromatase inhibitors versus any other endocrine treatment • Aromatase inhibitors versus no endocrine treatment • Aromatase inhibitors plus other endocrine treatment versus other endocrine treatment alone
• Direct comparison between different aromatase inhibitors
Types of outcome measures
Outcome measures were defined a priori as follows:
Primary outcome
Overall survival (defined as time from date of randomisation to date of death from any cause) Secondary outcomes 1. Progression-free survival (defined as time from date of randomisation to disease progression), also known as time to progression 2. Clinical response rate. This comprises objective response (those women with either complete or partial shrinkage of the tumour) and clinical benefit (objective response plus stable disease for more than 24 weeks)* 3. Treatment toxicity (particularly AI related) 4. Quality of life (QOL), where available and comparable 5. Dropout rate 6. Time to treatment end (stopped or changed due to toxicity) * International Union Against Cancer (UICC) guidelines for evaluation of these criteria (Hayward 1977) .
Subgroup analyses
Performed where data were sufficient
• first-line therapy (where the AI was given as initial therapy for advanced disease);
• second-line therapy (where the advanced disease had already been treated with a different AI or another endocrine therapy);
• ER positive versus ER unknown;
• according to site of distant metastases and differential treatment effect.
Search methods for identification of studies
The Cochrane Breast Cancer Group Specialised Register was first searched on 3 December 2004 using the codes for "advanced" and "endocrine therapy". Details of the search strategy applied to create the Register and the procedure used to code references are described in the Cochrane Breast Cancer Group module on The Cochrane Library. The Cochrane Central Register of Controlled Trials (CENTRAL) and relevant conference proceedings were also searched. Reference sections of each published paper were searched for additional studies. The authors subsequently updated the search to 30 September 2005.
Data collection and analysis
Assessing trials for eligibility Study selection Trials identified through the search strategy were reviewed by two of the authors (CLD, LJG) who independently decided on eligibility; any differences were resolved by discussion and confirmed by a third author (DJL). Any exclusions have been justified and documented in the table Characteristics of excluded studies. Quality control and peer review Two authors (LJG and CLD) made an independent assessment of the quality of the trial based on the quality of the randomisation. For unpublished trials, information has been obtained from the protocol or other available source; however unpublished trials were not included in the review but are included in the ongoing trials. Where information was missing or additional information was required the authors were contacted but only two replies were received.
Assessment of the methodological quality
The quality of all studies deemed eligible was reviewed independently by two review authors (LJG, CLD) and discrepancies were resolved by discussion. The quality of each study was assessed based on reports in the publication on: -quality of randomisation; -comparability between the baseline characteristics of the treatment arms; -inclusion of all randomised participants in the analysis; -details of dropouts. Randomisation was assessed by grading the allocation concealment (for example blinded, stratified) as A = adequate, B = unclear, C = inadequate (see Characteristics of included studies). It was not possible to assess the quality of randomisation accurately in all studies due to lack of information in the published articles. Any imbalance between treatment arms, both in numbers and characteristics, was taken into account in the grading. Intention-to-treat statements: analyses that were stated to be by intention to treat included all randomised patients for the primary endpoint. However, it is common practice to report response variables, that is clinical benefit and objective response, only on 'assessable' patients. We have reported these outcomes on both assessable and randomised patients. Description of the eligibility and exclusion criteria: all studies described in detail the patient characteristics of those patients eligible for the study. The table Characteristics of included studies includes information on the balance of baseline characteristics, details of patients excluded after randomisation, definitions of the outcome measures, duration of follow up and median length of follow up.
Data extraction
Data extraction was performed independently by two of the review authors (CLD, LJG) using data extraction forms designed for the purpose. Data extracted included details of treatment arms and patient numbers, baseline patient characteristics, tumour response rates, time to progression, median survival and median follow up. Data on toxicity and quality of life were extracted at a later date. The authors were not blinded to the source of the document for article selection or data extraction. A third author (DJL) assessed the data collected to ensure consistency and accuracy. Any differences were resolved by discussion. Data were extracted on quality as described in 'Assessment of the methodological quality'. Hazard ratios and their associated variances were extracted for all measures available. If a hazard ratio and confidence interval were not reported, these values were calculated (Parmar 1995). Of the report authors (n=8) who were contacted for supplementary information on the primary endpoints, only two replied (and the data were not available).
Analysis
The most complete dataset feasible was assembled. Data were, however, only available for the following endpoints: overall survival, progression-free survival, clinical benefit, objective response and toxicity. The Cochrane Review Manager software (RevMan) was used to analyse the data. Statistical heterogeneity between studies was assessed using the chi-squared statistic. Overall and progression-free survival were analysed using time-toevent methods and for this the hazard ratio (HR) is the most appropriate statistic. If a HR and corresponding confidence intervals (CI) were not reported, these values were calculated indirectly using median time to event (progression or survival) and the number of events extracted from the published Kaplan-Meier curves following the method of Parmar 1995. A weighted average of survival duration across studies was then calculated. A fixed effect model was used for the primary analyses (see the Cochrane Handbook for Systematic Reviews of Interventions) unless there was significant heterogeneity, in which case a random effects model was used. Ratios of treatment effects for time-to-event were reported so that HRs less than 1.0 favour the AI regimen. Response rates were obtained from the tables of best response presented for each trial. Response has been analysed based on assessable (not randomised) patients as most of the trials included in this review only reported response in this way. As a sensitivity analysis, we also analysed results by intention to treat (ITT) and there was no difference. Response rates were analysed as dichotomous variables (for example objective response compared complete or partial response versus stable disease or no response). An odds ratio (OR) and its associated 95% CI was calculated for each trial and a pooled OR derived. Ratios of treatment effects on response were reported so that ORs less than 1.0 favour the AI regimen. Not all toxicities (also known as side effects or adverse events) were reported in this review. We selected six predefined toxicities from expert experience, reflecting side effects specific to AIs (nausea, diarrhoea, rash, arthralgia) and other hormonal treatments (hot flushes, vaginal bleeding, thromboembolic events). Each side effect was analysed as a dichotomous variable (yes or no) with the effect of the AI considered separately to that of the comparator. This was deemed the most informative method of presentation as the different comparators have different toxicity profiles whereas AIs have similar toxicity profiles. An OR and its associated 95% CI were calculated for each trial and a pooled OR derived. Ratios of treatment effects for toxicity were reported so that ORs less than 1.0 favour the AI regimen. Not all trials had data on toxicity and for those that did the data were not consistent among trials. Toxicity data were available for only 22 of the trials comparing an AI with a non-AI. Within studies, the reported toxicities varied both in the number or range and type of toxicities reported as well as the criteria used for reporting. ) though what this means was not defined, two reported adverse experiences (Buzdar 1996b; Buzdar 1996c) and one reported all toxicities (Rose 1986). Four studies did not state which reporting criteria they used. In addition, one study (Perez Carrion 1994) only reported on the toxicities considered to be treatmentrelated and has not been included. Despite the different reporting criteria the data were pooled so this must be borne in mind when looking at the absolute numbers. One additional study (Dombernowsky 1998) mentioned that a QOL instrument was used at baseline and at each visit whilst on treatment but it was not mentioned as an endpoint nor were any data included. Three of the eight studies (Bezwoda 1998; Buzdar 1996b; Buzdar 1996c) did not report any QOL data. Only one (Thuerlimann 1997) has published two papers on the QOL data in detail. There are several reasons why the limited QOL data are not included in this review: heterogeneous changes among patients, that is different symptoms and side effect profiles; different methods of drug application, that is injection versus tablets; use of four different QOL instruments at several different timepoints; some results given as responders versus non-responders rather than by treatment groups; some QOL measures based on clinician-reported rather than patient-reported symptoms.
Quality of Life
Dropout rates
The number of actual dropouts was very difficult to quantify as the quantity and quality of reporting varied greatly. Numbers of patients were not given in six studies; numbers were not always given by treatment arm and only six studies gave full details. Three studies quoted the number of patients withdrawn due to toxicity as "a small number" (Buzdar 1996b; Buzdar 1996c; Kaufmann 2000). Thus the patients that could be confidently identified as lost to follow up, refusals or withdrawals totalled 51.
Time to treatment end
No studies specifically stated time to treatment end. However, all but three of the studies (Leitzel 1995; Powles 1984; Tominaga 2003) reported on at least one of the following: time to progression, time to failure or time to death, or both of the latter.
Results are presented graphically and all figures follow the same format. Each trial is presented as a single line within each category. The point estimate of the treatment effect is represented by a square, the size of which is proportional to the size of the study. The associated 95% CI is included as a horizontal line. The summary in each category is represented by a diamond, the north-south axis is the pooled estimate and the east-west axis is the 95% CI. A pooled analysis was performed in each group, but the results from each aromatase inhibitor (AI) were considered separately within the same group, where possible. This approach is considered to be more informative due to differences between the AIs (first versus second versus third generation; steroidal versus nonsteroidal). Post hoc, it was decided also to present the pooled results for the AIs in current clinical use (by definition the newer, third generation AIs) separately as this is more relevant to the clinical situation today. The AIs included were: aminoglutethimide (first generation), formestane (second generation), anastrozole, exemestane, fadrozole, letrozole and vorozole (third generation). The nonAIs included are megestrol acetate (MA), tamoxifen, fulvestrant, medroxyprogesterone acetate (MPA) and hydrocortisone (HC). In all cases, tests for heterogeneity have been performed across all studies and in each of the treatment groupings outlined above. Instances of statistically significant heterogeneity will be discussed in the results section. All analyses were based on the intention-to-treat principle (ITT) as far as possible, comparing all women allocated to one treatment versus all those allocated to the other, irrespective of compliance. Thus the result may slightly underestimate any treatment effects. However, analysis on response used the number of assessable women as the denominator, as this is the accepted method. As a sensitivity analysis, both denominators were used (see figures) and there was no major difference for response when comparing assessable to ITT. For statistical tests a P value of less than 0.05 was considered to denote statistical significance. The Cochrane Review Manager Software (RevMan4) was used to analyse the data.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies. The search strategy yielded 152 English-language references, of which 133 were possibly eligible. Twenty five of the 133 references, relating to 22 trials were excluded as they compared the same AI at different doses. However, if a study compared two doses of an AI with a comparator the study was included using the arm with the standard dose of that particular AI versus the comparator. Other references were excluded because they were either non-English language papers, reviews, non-randomised studies or conference proceedings without the addition of published data. The exception to this the conference abstract by Schmid 2001 which is included as it presented several of the endpoints of this review in abstract form and there is no published paper of this study. From these, 50 relevant references were identified relating to 25 randomised trials which fulfilled the eligibility criteria. An additional five references for five studies were identified by the authors from reference lists in papers and reviews. Thirty trials were included in this review and these trials randomised 11,208 women. There was a great deal of variation across studies. Trials ranged in size from 60 (Kleeberg 1997) to 1021 patients (Bonneterre 2001). Twelve studies randomised patients from multiple countries; of the remaining 18 studies, three were limited to the UK, two each from Spain and South America, and one from Canada, Denmark, Japan, Switzerland, and the US. The country was not reported in the remaining six studies. Within the 30 trials, 9723 women were randomised in 26 trials comparing AIs with non-AIs, and 1485 women were randomised in four trials of one AI versus a different AI. It should be noted that seven studies included two different doses of an AI compared with a third comparison. The decision was made to include only data from the arm of the study which included the most commonly used dose of the AI. For anastrozole this was 1 mg and for fadrozole 2.5 mg, or 2 mg if 2.5 mg was not used. The number of included randomised women for all 30 studies was 10,054. Of the 26 trials comparing AIs with non-AIs, seven used the first generation AI aminogluthetimide, two used the second generation AI formestane, and 17 used a third generation AI (anastrozole, four trials; exemestane, two; fadrozole, six; letrozole, four; vorozole, one). In these studies the comparator was tamoxifen in 11 trials, MA in 12, MPA in one, hydrocortisone (HC) in one and fulvestrant in one. The four trials of AIs versus a different AI compared letrozole versus aminoglutethimide and anastrozole, fadrozole, exemestane or anastrozole versus formestane. In 10 of the 30 studies (randomising 3635 women), any AI was used as first-line treatment versus any other comparator, which was tamoxifen in all of them. In 14 of 30 studies (5349 randomised women) any AI was compared with any comparator as secondline therapy. In the remaining seven trials the AIs were used as both first and second-line treatments within the trials but as the data were not split by this variable they were not included in these comparisons. Data for all endpoints were not available in the published reports. Thus five principal endpoints with sufficient data were identified: overall survival, progression-free survival, response (either based on clinical benefit or objective response) and treatment toxicity. These principal endpoints were not available from all papers. Where data were unavailable, authors were approached for supplementary data. Data were not available in the published reports for all groups outlined in the review protocol . The most data were available for the AI versus any non-AI group and therefore results for all five endpoints were presented as well as a subgroup consisting of data from the three most commonly prescribed AIs, that is anastrozole, exemestane and letrozole. In addition, the results of four of the five endpoints (not toxicity) outlined above are presented in three separate groups based on: individual AIs versus different AIs, AIs used as first-line treatment only, AIs used as second-line therapy only.
Risk of bias in included studies
Thirty randomised studies were included in this review. Non-randomised studies were excluded at the selection stage as they did not fulfil the inclusion criteria. One of the included studies did not have data on the primary or secondary endpoints so could not be included in any analysis. It should be noted that trials by the author of one of the included studies Bezwoda 1998, relating to high dose chemotherapy, have been found to include falsified data. However, no such findings have been reported for trials included in this review and there was therefore no reason to exclude this study. Analysis was performed with and without this study and there was no difference in the pooled results, although for clinical benefit the result became just significant. It was not possible to assess the quality of all studies accurately due to lack of information, including the quality of the randomisation process, in the published articles. Randomisation was rated as adequate in 18 studies but there were insufficient details of the randomisation process in the remaining 12 and so they were labelled as unclear. Of these, no randomisation method was given in six studies and four were reported to have parallel groups. No studies were deemed to have inadequate randomisation from the information given in the published papers and none were excluded for this reason. Baseline characteristics were not commented upon in 10 studies, five studies commented on a slight imbalance. One study (Buzdar 1996a) had an imbalance in the treatment arm but this was believed to be an artefact. All other studies reported balanced baseline characteristics in all arms. The AI arm in some of the older studies ( 
Summary of numbers of women used in the analysis
Women randomised, all arms = 11,208 Women randomised, included arms = 10,054 Women randomised, assessable (for response) = 8842
Effects of interventions
Over 10,000 women were randomised to the included arms of 30 trials, but time-to-event data was only available for about half of them. The results of the meta-analysis should be interpreted bearing this in mind.
Aromatase inhibitors versus any non-aromatase inhibitor
Of the 26 trials comparing an AI versus a non-AI one had no data on response or survival by treatment arm although these were included as endpoints (Leitzel 1995) . Of the remaining 25 trials, data were available on overall tumour response rates data in all 25, clinical benefit in 22, progression-free survival in 10 and overall survival in 12 trials. 
Overall survival
Data on survival were available in 12 trials reporting an estimated 2576 events in 4548 women. No data were available for formestane. The pooled HR of 0.89 (95% CI 0.82 to 0.96) shows a statistically significant 11% benefit of treatment (P = 0.003) with an AI, with a consistent effect across all subgroups. Data on individual AIs were sparse and no conclusions could be drawn.
Progression-free survival
Data on progression were available in 10 trials reporting an estimated 3791 events in 5355 women. Progression was not statically significantly associated with the use of an AI (HR 0.97, 95% CI 0.83 to 1.14). This overall effect is virtually uninterpretable due to the significant heterogeneity by type of AI and also within specific AIs. Exemestane was statistically significantly better than the non-AI whereas vorozole was significantly worse. The exemestane results are based on a single study. 
Toxicity
Not all trials had data on toxicity and for those that did the data were not consistent among all trials. Toxicity data were available for only 22 of the trials comparing an AI with a non-AI. Within studies, the reported toxicities varied both in the number or range and type of toxicities reported as well as the criteria used for reporting. Some studies reported predefined or selected toxicities , data on toxicity were obtained from different sources. The combined analysis of the two trials 0020 and 0021 reported predefined events and data on hot flushes and thromboembolic events were available. The separate publications of the results of 0020 and 0021 detailed toxicities occurring in 10% or more of the participants. Trial 0020 reported data on both nausea and vomiting so these were combined with these data from 0021. In addition, trial 0021 had data on the frequency of diarrhoea and rash. Four studies did not state which reporting criteria they used. One study (Perez Carrion 1994) only reported on the toxicities considered to be treatment-related and has not been included. Despite these reporting differences, data from all trials were pooled as otherwise there would have been too few data for each comparator and symptom. The analyses have been split according to the comparator due to the different toxicity profiles of each comparator and so the pooled results have not been reported.
Hot flushes
Hot flushes was the specific toxicity that was most widely reported. Data on hot flushes were available from 18 studies with 7059 women. Of these, seven compared an AI with tamoxifen, nine with MA and one each with fulvestrant and MPA. The use of an AI had very similar risk of hot flushes to tamoxifen and fulvestrant. The AI was associated with statistically signficantly more reports of hot flushes than with MA (OR 1.77, 95% CI 1.42 to 2.20) but less than with MPA (OR 0.20, 95% CI 0.06 to 0.73) which had data from only one trial. Nausea Data on nausea were available from 15 studies with 6602 women. Another two trials reported data on nausea and vomiting combined. Of the 15, six compared an AI with tamoxifen, eight with MA and one with fulvestrant. AIs were associated with a statistically significant increase in risk of nausea compared to MA (OR 1.84, 95% CI 1.37 to 2.47) but there was no statistically significant difference between AIs and tamoxifen (P = 0.32) or fulvestrant (P = 0.81). Vomiting Two studies had data on nausea and vomiting combined and so were not included. Data on vomiting were available from two studies comparing AIs with tamoxifen, five versus MA and one versus fulvestrant for a total of 4404 women. The AI was statistically significantly worse when compared to MA (OR 2.03, 95% CI 1.42 to 2.90). The comparisons with tamoxifen and fulvestrant suggested no statistically significant differences. Diarrhoea Nine studies with 4507 women had data on diarrhoea toxicity. Of these, three compared an AI with tamoxifen, five with MA and one with fulvestrant. AIs were associated with a statistically significant higher rate of diarrhoea than either tamoxifen (OR 1.64, 95% CI 1.06 to 2.55) or MA (OR 1.48, 95% CI 1.02 to 2.13) but not fulvestrant (P = 0.19).
Rash
Twelve studies with 3822 women had data on rash toxicity. Of these, four compared an AI with tamoxifen, six with MA, and one each with MPA and fulvestrant. AIs were associated with a statistically significant increased risk of rash when compared with tamoxifen (OR 33.61, 95% CI 4.71 to 239.97) and for the one trial versus MPA (OR 111.71, 95% CI 6.75 to 1849.91) but not against MA or fulvestrant . Within the comparison with MA there was statistically significant heterogeneity (P = 0.0005).
Vaginal bleeding
Data on vaginal bleeding were reported in four studies of 2150 women, two compared an AI with MA and one each with tamoxifen and MPA. Compared with MA, there was a statistically significant benefit of 71% to treatment with the AI (OR 0.29, 95% CI 0.13 to 0.65). The one trial versus MPA also found a statistically significant difference with an OR of 0.10 (95% CI 0.01 to 0.77). There was no statistically significant difference between AIs and tamoxifen (P = 0.15)..
Thromboembolic events
Thromboembolic event data were available from six studies with 2937 women. Two compared an AI with tamoxifen, three with MA and one with fulvestrant. The AI had a statistically significant advantage over tamoxifen (OR 0.48, 95% CI 0.27 to 0.85) only.
Arthralgia
Data on arthralgia were available for 2470 women in two studies versus tamoxifen (N = 1031) and four studies versus MA (N = 1439). There was no statistically significant difference between the AIs and either tamoxifen or MA. The results varied by type of AI with only exemestane (one trial only) being statistically significantly better than the non-AI and there was no evidence of an effect for anastrozole. There was significant heterogeneity both in the pooled result (P<0.00001) and within the anastrozole trials (P<0.00001).
Proportion of women with clinical benefit (5079 assessable women)
Data were available from 10 trials. The pooled OR suggested a statistically significant advantage to the AI of 22% (OR 0.78, 95% CI 0.63 to 0.96). There was statistically significant heterogeneity among the trials (P = 0.002).
Proportion of women with objective response (5079 assessable women)
All 10 trials reported objective response. The pooled OR of 0.77 (95% CI 0.62 to 0.96) showed a statistically significant advantage to the AI but there was statistically significant heterogeneity (P = 0.03) across the trial results. There was also significant heterogeneity within the exemestane trials.
Toxicity
One of the suggested benefits of the third generation AIs is a reduced toxicity profile. Therefore toxicity data were extracted for the three most commonly used AIs at this time, that is anastrozole, exemestane and letrozole. The results were presented by comparator as the comparators have different toxicity profiles whereas the AIs have similar toxicity profiles. The denominators for the comparison of anastrozole with fulvestrant vary depending on whether the combined trial results were available (hot flushes, nausea, vomiting, thromboembolic events) or not (diarrhoea, rash).
Hot flushes
Hot flushes was the specific toxicity that was reported most widely. Data on hot flushes were available from eight of the 10 studies, with 4930 women. Three studies compared the AI with tamoxifen, four with MA and one with fulvestrant. The use of an AI had a very similar risk of hot flushes to tamoxifen and fulvestrant but was associated with statistically significant more reports of hot flushes than with MA (OR 1.69, 95% CI 1.24 to 2.30).
Nausea
Data on nausea were available from eight of the 10 studies, with 4930 women. Of the eight studies, three compared an AI with tamoxifen, four with MA and one with fulvestrant. The AIs had statistically signicantly more reports of nausea than MA (OR 1.45, 95% CI 1.09 to 1.95) but there was no statistically significant difference when the AIs were compared to tamoxifen or fulvestrant. Vomiting Five studies with 3499 women had data on vomiting alone and only one made the comparison with tamoxifen. There was no statistically significant differences between the AI and either tamoxifen or fulvestrant. Compared with MA, the AIs had a statistically significantly increased risk of vomiting (OR 1.77, 95% CI 1.11 to 2.83). Diarrhoea Six studies with 3602 women had data on diarrhoea toxicity. Two compared an AI with tamoxifen, three with MA and one with fulvestrant. There was a statistically significant increased risk of diarrhoea with the AIs against MA (OR 2.40, 95% CI 1.34 to 4.29). Rash Four studies with 2033 women comparing AIs with MA or ful-vestrant had data on rash. AIs were not associated with a statistically significant increased risk of rash and there was statistically significant heterogeneity among the three studies with MA as the comparator (P = 0.04).
Vaginal bleeding
Data on vaginal bleeding were reported in three studies with 1932 women, one compared an AI with tamoxifen and two with MA. There was a statistically significant benefit to treatment with the AIs in comparison with MA (OR 0.29, 95% CI 0.13 to 0.65).
Thromboembolic events
Thromboembolic event data were available for 2378 women in three studies but there was only one study per comparator (tamoxifen, MA or fulvestrant). AIs were associated with a statistically significantly lower incidence of thromboembolic events than tamoxifen (OR 0.53, 95% CI 0.29 to 0.96) but not compared with MA or fulvestrant. Arthralgia Data on arthralgia as a specific side effect were only available for 1394 women in three studies, two versus tamoxifen and one versus MA. Against both comparators, the AI was not statistically significantly associated with a difference in the incidence of arthralgia.
Other analyses Aromatase inhibitors versus any different aromatase inhibitor
A total of 1481 women in four trials were randomised to one AI versus a different AI. Of these, all four had data on response but only one had results on overall survival and progression-free survival (Gershanovich 1998). Letrozole was compared with a different AI in all the trials (Gershanovich 1998, Rose 2003, Tominaga 2003) except that of Kleeberg 1997 which compared anastrozole with formestane. The study by Rose and colleagues (Rose 2003) compared letrozole to anastrozole and in this section has been included in both the letrozole and anastrozole groups.
Overall survival
The Gershanovich 1998 study cited above was the only one in this section that had data on overall survival. Letrozole had a statistically significant reduced HR of 0.64 (95% CI 0.49 to 0.84) giving a 36% advantage in survival over aminoglutethimide treatment.
Progression-free survival
Only one study had data on progression from 551 women (Gershanovich 1998). In this study, letrozole was associated with a reduced hazard (HR 0.72, 95% CI 0.57 to 0.91) showing a 28% advantage in terms of progression-free survival compared to aminoglutethimide. 3. Proportion of assessable women with clinical benefit (1152 assessable patients) Data were available from 1152 assessable women. Letrozole was statistically significantly associated with a statistically significant clinical benefit compared with a different AI (OR 0.72, 95% CI 0.56 to 0.93). There was no significant study heterogeneity, P = 0.57.
Proportion of assessable women with objective response (1152 assessable patients)
Data were available from 1152 assessable women. The pooled overall result is not presented as Rose 2003 was included in both individual AI comparisons and so would be counted twice. Letrozole was statistically significantly different from any other AI (OR 0.53, 95% CI 0.39 -0.73). Results of all letrozole studies are consistent (test for heterogeneity P = 0.45). Anastrozole appeared to be significantly inferior to a different AI (OR 1.59, 95% CI 1.07 to 2.37).
Aromatase inhibition as first-line therapy versus any other therapy (tamoxifen)
Ten studies that randomised 3635 women used AIs exclusively as first-line therapy for advanced (metastatic) disease and all comparisons were against tamoxifen. We did not include any studies that were mixed first and second-line. Data from two studies with 1242 women (anastrozole and fadrozole) were available for overall survival and three studies with 2139 women (one study each on formestane, anastrozole, and letrozole) for progressionfree survival. All 10 studies reported results for objective response and eight studies for clinical benefit.
Overall survival
Data were only available from two studies with 1242 women, one each on anastrozole and fadrozole. There was no statistically significant difference in the effect of treatment with an AI compared to tamoxifen.
Progression-free survival
Data were available from three of the 10 studies. The first-line AI regimen was statistically significantly superior to tamoxifen with a decreased hazard of 0.78 (95% CI 0.70 to 0.86). Anastrozole (Bonneterre 2001) and letrozole (Mourisden 2001) were statistically significantly different from tamoxifen (reduced hazard of 18% and 30%, respectively).
Clinical benefit (3036 assessable women)
Data on clinical benefit were available from 3036 assessable women. As results for individual AIs, except for aminoglutethimide and anastrozole, were based on only a single study the pooled result is emphasised. The AIs were significantly better than tamoxifen as first-line therapy (OR 0.70, 95% CI 0.51 to 0.97) but there was significant heterogeneity across the AIs (P = 0.001). The individual results for exemestane and letrozole were statistically significant in the analysis of assessable women but for letrozole only based on the analysis of randomised women.
Proportion of assessable women with objective response (3287 assessable women)
Data on objective response were available from 3287 assessable women. Aminoglutethimide was the only AI with more than two studies published. The AIs were not statistically significantly bet-ter than tamoxifen as first-line therapy. There was considerable heterogeneity (P = 0.006) by type of AI. Exemestane and letrozole were the only AIs that were statistically significantly better than tamoxifen but in both cases the results are only based on one study. The other AIs appear to have little impact on objective response.
Aromatase inhibition as second-line therapy versus any other therapy
Women who had previously been treated with endocrine therapy, either a different AI or non-AI, for advanced (metastatic) disease and received the study AI as second-line therapy were included in 14 trials. Aminoglutethimide was used as second-line in three studies, formestane in one, anastrozole in two, exemestane in one, fadrozole in three, letrozole in two and vorozole in one. The majority of the comparisons (10) were against MA. One trial (Rose 2003) which compared anastrozole to letrozole was not included in the analysis. We did not include trials where there was a mixture of first and second-line therapy. Data on objective response were available from all of the trials, clinical benefit from 11 trials, HRs for progression-free survival from six trials and HRs for overall survival from two trials.
Overall survival
Data on overall survival were limited, with data from two trials of different AIs, anastrozole and letrozole. Second line treatment with an AI was statistically significantly associated with a decreased hazard of death (HR 0.80, 95% CI 0.66 to 0.96). This effect was consistent for both AIs (heterogeneity P = 0.79).
Progression-free survival
AI use was not associated with a statistically significant difference in the risk of progression. There was significant heterogeneity (P = 0.0002) across studies with use of either anastrozole or vorozole associated with a significantly increased risk of progression and exemestane associated with a statistically significant decrease.
Proportion of assessable women with clinical benefit (3721 assessable women)
There did not appear to be any effect in terms of a statistically significant clinical benefit when an AI was used as second-line therapy. This lack of effect was consistent across AI subgroups (heterogeneity P = 0.95).
Proportion of assessable women with objective response (4170 assessable women)
Overall there was no statistically significant difference between the use of an AI as second-line therapy and any other therapy. When looking at individual AIs none showed any evidence of a benefit, but this was based on small numbers. There was no statistical heterogeneity (P = 0.33) .
D I S C U S S I O N
This review demonstrates that there is a survival benefit of 11% from using AIs for the treatment of advanced (metastatic) breast cancer. This finding is not consistent across all AIs, with the greatest benefit associated with the AIs in current clinical use, namely anastrozole, exemestane and letrozole. However, data on survival were only available for about half of the women and one of the trials (Buzdar 1996a) was not designed or powered to detect significant differences in survival.
The positive effects of AIs in terms of tumour response when given as first or second-line therapy were statistically significant for firstline therapy where the comparator was tamoxifen. There were no data available on other comparators. When comparing the effect of the AI as second-line therapy there was no statistically significant difference when considering tumour response. In terms of progression-free survival, there was a statistically significant decreased hazard of progression for treatment with the AIs as first line-therapy only. The paucity of data makes it difficult to make any firm conclusions in terms of overall survival.
In terms of toxicity, AIs are known to be associated with a higher incidence of nausea, diarrhoea, rash and arthralgia but a lower risk of vaginal bleeding and thromboembolic events. There was a higher incidence of hot flushes with AIs when compared to MA but not when compared to tamoxifen. However, combining data across studies was difficult as both the toxicities reported and the criteria for reporting toxicities, if they were reported at all, varied greatly.
This review has combined data from a wide variety of studies that were carried out over 20 years. Some of the trials did not use an AI as a single agent but in combination with another endocrine therapy. There was heterogeneity both across types of AI and within each AI. The results of studies of three generations of AIs have been combined as well as results from studies of steroidal and nonsteroidal therapy. This has been forced to some extent by the lack of data on individual AIs.
Evidence of heterogeneity between trials was identified for tumour response rates and progression-free survival though not overall survival. The reasons for this are unknown but this statistical heterogeneity may be explained by clinical heterogeneity. It may be that outcomes involving subjective endpoints, that is tumour response, may be subject to variation whereas the hard endpoint used in the survival analysis is unequivocal. Other contributory factors may be the difference in dosage of some AIs and significant differences in the proportion of patients who were truly hormone receptor positive.
Within each AI, studies varied in terms of sample size, dose of AI, comparison regimen, outcomes, length of follow up and quality of reporting. For example, the seven studies of aminoglutethimide consisted of between 62 and 313 patients; three of the studies were of first-line therapy, three second-line and one mixed. Doses of aminoglutethimide used were 125 mg in one study, 250 mg* in one, 500 mg* in three, 750 mg in one and 1000 mg in one (* dose doubled after a specific period of treatment). The comparator was tamoxifen in four studies (20 mg in two, 30 mg in one, 40 mg in one), MA 160 mg in one, MPA 1000 mg in one and HC 20 mg in one. Not all endpoints were available in each study: three reported overall survival, two progression-free survival, five clinical benefit and seven objective response.
There are very limited data on quality of life reported in this setting. The limited quality of life data which was reported did not show any significant differences between the AI and comparator groups, however some differences were found with some subscales in favour of the AI (Goss 1999; Kaufmann 2000). The patient's perspective in advanced disease treatment is an important endpoint and should be included in studies as it would aid interpretation in this mainly palliative setting.
A lack of standardised reporting of clinical endpoints impacted upon the analysis of all AIs, not just aminoglutethimide. Therefore, it was not possible to include all studies in each section, which impacted on the power of certain analyses, especially overall and progression-free survival. In addition, many of the data required to carry out analyses of prospectively identified subgroups, as set out in the review protocol were not available. We could not, therefore, identify specific subgroups of women who may benefit from AI use.
If the description of randomisation is used as a barometer of reporting trial quality, it appears that this has improved over time. For example, in the studies of the first generation AI aminoglutethimide, six of seven randomisations were categorised as unclear whereas only two of the seven third generation AI letrozole trials were considered as such.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Historically, the treatment for advanced (metastatic) breast cancer has been with hormonal treatments such as tamoxifen or the progestins MA or MPA. This review confirms a survival benefit of treating advanced (metastatic) breast cancer with the third generation aromatase inhibitors (anastrozole, exemestane and letrozole) that are being used clinically today.
Implications for research
This review would benefit from additional publications with greater survival details, that is median survival and number of events, for those studies that did not publish them originally. Further data from exemestane trials are required to evaluate this AI more completely. Efforts should be made to standardise reporting of toxicity, and a quality of life component should also be included. 
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